Serum Metrnl Level is Correlated with Insulin Resistance, But Not with β-Cell Function in Type 2 Diabetics.

BACKGROUND Metrnl is a novel identified adipomyokine which might have therapeutic potential for metabolic and inflammatory diseases, including type 2 diabetes mellitus. We aimed to explore the associations of circulating Metrnl level with ß-cell function and insulin resistance (IR) and further explore the possible correlation between Metrnl and another adipomyokine named irisin in patients diagnosed type 2 diabetes. MATERIAL AND METHODS Our study recruited 59 participants with type 2 diabetes and 30 normal glucose tolerance (NGT) participants. We used enzyme-linked immunosorbent assay (ELISA) to measure serum levels of Metrnl and irisin. The associations of Metrnl level with indexes of ß-cell function and IR and irisin level were analyzed by multiple linear regression analysis or spearman correlation analysis. RESULTS Compared with NGT participants, serum Metrnl level was elevated in participants with type 2 diabetes: 210.30 pg/mL (range 105.94-323.91 pg/mL) versus 132.02 pg/mL (range 104.93-195.92 pg/mL). Metrnl level did not show significant correlation with ß-cell function-related indicators, but positively correlated with HOMA2-IR and negatively correlated with HOMA2-%S after controlling multiple covariates in participants with type 2 diabetes. Metrnl level was also not associated with obesity-related indicators (body mass index, waist circumference, body fat percentage, and visceral adipose tissue area) in the type 2 diabetes group. In addition, the correlation between Metrnl and irisin level was also not present (r=-0.159, P=0.229) in type 2 diabetes group. CONCLUSIONS Serum Metrnl level was associated with IR, but not with ß-cell function in participants with diagnosed type 2 diabetes.